Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.68 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.68 |
| ▸ | CLK2 | P49760 | 1/20 | 0.68 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | CDC7 | O00311 | 6/20 | 0.41 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.37 |
| ▸ | CCNC | P24863 | 1/20 | 0.37 |
| ▸ | CDK8 | P49336 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7685369 | 0.82 | CSNK1A1 (1.00) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7687649 | 0.79 | CSNK1A1 (0.81) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7742023 | 0.79 | CSNK1A1 (0.93) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7685357 | 0.79 | CSNK1A1 (0.65) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7692080 | 0.77 | CSNK1D (0.88) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7689330 | 0.77 | CSNK1D (0.77) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7681361 | 0.77 | CSNK1D (0.88) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7690547 | 0.75 | CSNK1A1 (0.78) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7689235 | 0.75 | CSNK1A1 (0.78) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 | |
| SCHEMBL7686242 | 0.75 | CSNK1A1 (0.73) | CSNK1A1CSNK1DCLK2CSNK1G1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417202-B1 | 3-ACETYL-4-METHYL-2,5-DI(4-PYRIDYL)-1H-PYRROLE, FOR EXAMPLE; TREATING CELL ADHESION MOLECULES (CAMS) MEDIATED DISEASES SUCH AS ARTHRITIS, AIDS, SEPTIC SHOCK, CACHEXIA, TRANSPLANT REJECTION | PFIZER INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | PFIZER PHARMACEUTICALS INC. (JP) | 2002-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049235-A1 | 3-acetyl-4-methyl-2,5-di(4-pyridyl)-1H-pyrrole, for example; treating cell adhesion molecules (CAMs) mediated diseases such as arthritis, AIDS, septic shock, cachexia, transplant rejection | ICAM1, VCAM1, CD14 | CSNK1A1 2321/4885CSNK1D 2460/4885CLK2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.